Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome

European Journal of Cancer

Volumn 51, Issue 17, 2015, Pages 2501-2507

  Monzon, Jose G ^a   Hay, Annette E ^b   McDonald, Gail T ^b   Pater, Joseph L ^b   Meyer, Ralph M ^c   Chen, Eric ^d   Chen, Bingshu E ^b   Dancey, Janet E ^b  

^a TOM BAKER CANCER CENTRE   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Clinical trials; Phase 2; Randomised; Single arm

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SOLID TUMOR; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; DRUG THERAPY; METHODOLOGY; NEOPLASMS; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; REMISSION; STANDARDS;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DRUG THERAPY; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84948379888     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.08.004     Document Type: Article

References (19)

1. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 8 2004 711 715
2. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs J Health Econ 22 2 2003 151 185
3. R. Collier Drug development cost estimates hard to swallow CMAJ 180 3 2009 279 280
4. J.A. DiMasi, and H.G. Grabowski Economics of new oncology drug development J Clin Oncol 25 2 2007 209 216
5. D.J. Stewart, S.N. Whitney, and R. Kurzrock Equipoise lost: ethics, costs, and the regulation of cancer clinical research J Clin Oncol 28 17 2010 2925 2935
6. R.H. El-Maraghi, and E.A. Eisenhauer Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III J Clin Oncol 26 8 2008 1346 1354
7. S.A. Cannistra Phase II trials in journal of clinical oncology J Clin Oncol 27 19 2009 3073 3076
8. H.K. Gan, A. Grothey, G.R. Pond, and et al. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 28 15 2010 2641 2647
9. M.R. Sharma, W.M. Stadler, and M.J. Ratain Randomized phase II trials: a long-term investment with promising returns J Natl Cancer Inst 103 14 2011 1093 1100
10. H. Tang, N.R. Foster, A. Grothey, and et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials J Clin Oncol 28 11 2010 1936 1941
11. M.R. Sharma, T.G. Karrison, Y. Jin, and et al. Resampling phase III data to assess phase II trial designs and endpoints Clin Cancer Res 18 8 2012 2309 2315
12. L.V. Rubinstein, E.L. Korn, B. Freidlin, and et al. Design issues of randomized phase II trials and a proposal for phase II screening trials J Clin Oncol 23 28 2005 7199 7206
13. L. Rubinstein, M. Leblanc, and M.A. Smith More randomization in phase II trials: necessary but not sufficient J Natl Cancer Inst 103 14 2011 1075 1077
14. Z. Mohamed, D.J. Pinato, F.A. Mauri, and et al. Inflammation as a validated prognostic determinant in carcinoma of unknown primary site Br J Cancer 110 1 2014 208 213
15. S. Hunsberger, Y. Zhao, and R. Simon A comparison of phase II study strategies Clin Cancer Res 15 19 2009 5950 5955
16. J.K. Chan, S.M. Ueda, V.E. Sugiyama, and et al. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol 26 9 2008 1511 1518
17. M.I. Zia, L.L. Siu, G.R. Pond, and E.X. Chen Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens J Clin Oncol 23 28 2005 6982 6991
18. H.K. Gan, B. You, G.R. Pond, and E.X. Chen Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer J Natl Cancer Inst 104 8 2012 590 598
19. J. Péron, G.R. Pond, H.K. Gan, and et al. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review J Natl Cancer Inst 104 13 2012 982 989